Corporate Information

Isofol includes first patient in a clinical phase Ib/II study of arfolitixorin

By

GOTHENBURG, Sweden, April 28, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces that the first patient has been included in the clinical phase Ib/II study of the drug candidate arfolitixorin as a new potential treatment of metastatic colorectal cancer. The information in the press release is intended for investors. The clinical study aims […]

Isofol includes first patient in a clinical phase Ib/II study of arfolitixorin Read More »

Notice to attend the Annual General Meeting held on May 21, 2025 in Isofol Medical AB (publ)

By

GOTHENBURG, Sweden, April 17, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites the shareholders of Isofol Medical AB (publ), Reg. No. 556759-8064 based in Gothenburg, to the Annual General Meeting on Wednesday, May 21, 2025. The information in the press release is intended for investors. The shareholders in Isofol Medical AB (publ),

Notice to attend the Annual General Meeting held on May 21, 2025 in Isofol Medical AB (publ) Read More »

Isofol’s partner Solasia intends to increase investments in upcoming trials with arfolitixorin

By

GOTHENBURG, Sweden, April 3, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces that the company’s Japanese development and commercialization partner, Solasia Pharma K.K., intends to invest approximately 140 MSEK in the upcoming phase II and III trials of arfolitixorin in Japan and a subsequent regulatory submission for the treatment of metastatic colorectal cancer.

Isofol’s partner Solasia intends to increase investments in upcoming trials with arfolitixorin Read More »

Isofol etablishes advisory board with leading experts

By

GOTHENBURG, Sweden, March 27, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has established an advisory board with leading oncologists and colorectal cancer experts from the US, Europe and Japan. The advisors will play an important role in the continued development of the drug candidate arfolitixorin and the clinical

Isofol etablishes advisory board with leading experts Read More »

Isofol receives regulatory approval to initiate clinical study of arfolitixorin

By

GOTHENBURG, Sweden, March 21, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the regulatory authority in Germany, BfArM, has given their final approval for the initiation of the new clinical trial of the company’s drug candidate arfolitixorin. The study will initially be conducted in Germany, where patient recruitment will commence shortly.

Isofol receives regulatory approval to initiate clinical study of arfolitixorin Read More »

Isofol expands network of advisors with prominent expert

By

GOTHENBURG, Sweden, March 17, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has expanded its network of advisors with Godefridus (Frits) J. Peters, a prominent expert on the pharmacology of anticancer treatments and key opinion leader (KOL) active at the Amsterdam University Medical Center and other institutions. The information

Isofol expands network of advisors with prominent expert Read More »

Isofol presents at Stora Aktiedagarna on March 12

By

GOTHENBURG, Sweden, March 12, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces that the company’s CEO will present the company and its drug candidate arfolitixorin at Stora Aktiedagarna in Stockholm today, Wednesday March 12. The information in the press release is intended for investors. Today, Wednesday, March 12, at 1:30-1:55 p.m., Petter Segelman

Isofol presents at Stora Aktiedagarna on March 12 Read More »

Isofol presents at several upcoming investor meetings

By

GOTHENBURG, Sweden, March 5, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces that the company will participate in several investor and partnering meetings during the spring, to present the company and its drug candidate arfolitixorin. The information in the press release is intended for investors. Isofol’s CEO Petter Segelman Lindqvist will present Isofol

Isofol presents at several upcoming investor meetings Read More »

Isofol appoints Roger Tell as Chief Medical Officer ahead of initiation of clinical study

By

GOTHENBURG, Sweden, February 3, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that Roger Tell has been appointed Chief Medical Officer at Isofol ahead of the initiation of the planned clinical study. The information in the press release is intended for investors. Dr. Roger Tell (MD, PhD) has been active at Isofol

Isofol appoints Roger Tell as Chief Medical Officer ahead of initiation of clinical study Read More »

Isofol announces the presentation of a post-hoc analysis of the phase III study AGENT at the 2025 ASCO GI symposium

By

GOTHENBURG, Sweden, January 27, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that an abstract of the post-hoc per-protocol analysis of the global phase III study AGENT, showing results in favor of arfolitixorin, was presented at the 2025 ASCO GI meeting in San Francisco, California, USA, on January 25. These positive data,

Isofol announces the presentation of a post-hoc analysis of the phase III study AGENT at the 2025 ASCO GI symposium Read More »

Scroll to Top